Day: July 1, 2021

Chart Industries Acquires L.A. Turbine

Written by Customer Service on July 1, 2021. Posted in Mergers And Acquisitions.

ATLANTA, July 01, 2021 (GLOBE NEWSWIRE) — Chart Industries, Inc. (“Chart”) (NYSE: GTLS) today announced the acquisition of L.A. Turbine (“LAT” or “L.A. Turbine”) for $80 million in cash (subject to certain customary adjustments). L.A. Turbine is a global leader in turboexpander design, engineering, manufacturing, assembly and testing process for new and aftermarket equipment, with significant in-house engineering expertise. Expanders are utilized in the following Chart offerings, and with LAT in the Chart portfolio, we now can offer a more comprehensive “one stop shop” solution and provide more options for our customers in these applications:Hydrogen & helium liquefaction Carbon capture and energy storage Industrial gas Natural gas processing Small-scale LNG plants Propane dehydrogenation (PDH) plants Heavy hydrocarbon...

Bowlero, World’s Largest Owner and Operator of Bowling Centers and Owner of the Professional Bowlers Association, to List on NYSE Through Merger With Isos Acquisition Corporation

Written by Customer Service on July 1, 2021. Posted in Mergers And Acquisitions.

Merger with Isos Acquisition Corporation (NYSE: ISOS.U) supports further expansion of Bowlero’s large, profitable and growing business. Pro forma implied enterprise value of the combined company is approximately $2.6 billion. Transaction includes $450 million PIPE anchored by institutional investors including funds managed by affiliates of Apollo Global Management, Inc., Brigade Capital Management, Soros Fund Management LLC, The Donerail Group LP and Wells Fargo Asset Management. Total pre-pandemic trailing twelve months (TTM) through Feb 2020 revenue and EBITDA were $746 million and $201 million, respectively. Revenue and EBITDA for calendar year 2022 are expected to be $859 million and $275 million, respectively. Bowlero’s proven growth plan includes many powerful vectors, such as upgrades and conversions of its current centers, development...

Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress

Written by Customer Service on July 1, 2021. Posted in Earnings Releases And Operating Results.

AFM13 monotherapy: Reported positive outcome from the preplanned interim analysis for the registration-directed trial in PTCL; enrollment expected to be completed in the first half of 2022. AFM13 combination with NK cells: Announced 100% objective response rate in the first four response evaluable patients, including two complete responses. All three dose escalation cohorts are now fully enrolled; data update expected in the second half of 2021. AFM13 preclinical data: AFM13 in combination with natural killer (NK) cells demonstrated improved tumor recognition and enhanced tumor cell killing in vitro and in vivo. AFM24 monotherapy: AFM24 (phase 1/2a study) completed cohort 5 and is enrolling and treating patients in cohort 6; expansion cohorts expected to start in the second half of 2021. AFM24 combination with NK cells: Combination therapy...

Proactive news headlines including Buru Energy, Cobalt Blue Holdings, Technology Metals Australia and Theta Gold Mines

Written by Customer Service on July 1, 2021. Posted in Mergers And Acquisitions.

Sydney, July 01, 2021 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:Buru Energy Limited’s (ASX:BRU) (OTCMKTS:BRNGF) (FRA:BUD) shares are trading about 3.33% higher intra-day after spudding the Currajong 1 exploration well at 10:00 hours on Thursday, July 1 2021. Click here Cobalt Blue Holdings Ltd (ASX:COB) (OTCMKTS:CBBHF) (FRA:COH) CEO Joe Kaderavek has demonstrated his confidence in the company’s integrated cobalt strategy focus on the traditional NSW mining centre of Broken Hill through a series of on-market purchases. Click here Technology Metals Australia Ltd (ASX:TMT) (FRA:TN6) has ‘project defining’ pilot-scale test-work underway at the Yarrabubba Iron-Vanadium Project in Western Australia in support...

NewAge, Inc., Honored by Hermes Awards for Its Direct-to-Consumer and Social Media Marketing

Written by Customer Service on July 1, 2021. Posted in Public Companies.

Five-time award winner for excellence in the social media, social campaigns and advertising, and its development of the NewAge Share™ appLucim product familyLucim product familyDENVER, July 01, 2021 (GLOBE NEWSWIRE) — NewAge, Inc. (Nasdaq: NBEV), the Colorado-based organic and healthy products company intending to become the world’s leading social selling and distribution company, today announced that NewAge, Inc. has been honored as a five-time award winner in both direct-to-consumer marketing and corporate image categories in the Hermes Creative Awards Competition. Hermes Creative Awards is an international competition for creative professionals involved in the concept, writing and design of traditional and emerging media. Hermes Creative Awards recognizes outstanding work in the industry while promoting the...

Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo

Written by Customer Service on July 1, 2021. Posted in Public Companies.

Formulation-related observations from ARQ-252 trial in chronic hand eczema informed early termination of Phase 2a ARQ-252 trial in vitiligo Company progressing new formulation with goal of greater drug delivery to targets in the skinWESTLAKE VILLAGE, Calif., July 01, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), today announced its decision to terminate the recently initiated Phase 2a clinical trial evaluating ARQ-252, a topical small molecule inhibitor of Janus kinase type 1 (JAK1), as a potential treatment for vitiligo (ARQ-252-213). Arcutis’ decision is based on further analyses of the ARQ-252 drug formulation used in both this vitiligo study and the recently completed Phase 2b study evaluating ARQ-252 for the treatment of chronic hand eczema (ARQ-252-205). As previously announced, the Phase 2b chronic...

Armada Hoffler Properties to Discuss Second Quarter Earnings on August 3rd

Written by Customer Service on July 1, 2021. Posted in Public Companies.

VIRGINIA BEACH, Va., July 01, 2021 (GLOBE NEWSWIRE) — Armada Hoffler Properties, Inc. (NYSE: AHH) will report its earnings for the quarter ended June 30, 2021 at approximately 6:00 a.m. Eastern on Tuesday, August 3, 2021. At 8:30 a.m. Eastern on the same day, senior management will host a conference call and webcast to discuss earnings and other information. To listen to the call, dial 877-407-3982 (domestic) or 201-493-6780 (international) approximately 10 minutes prior to the start time of the call. The conference call will also be available through the investors page of the Company’s website, ArmadaHoffler.com. A telephonic replay will be available shortly after the conclusion of the call through Friday, September 3, 2021. This replay may be accessed by dialing 844-512-2921 (domestic) or 412-317-6671 (international) and providing...

GBT Evaluating Hybrid Frequency Solutions For Its Long-Range Radio System

Written by Customer Service on July 1, 2021. Posted in Public Companies.

Aiming to facilitate long distance, reliable, secured communications SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) — GBT Technologies Inc. ( OTC PINK: GTCH ) (“GBT” or the “Company”), is now evaluating and testing a hybrid solution for an efficient, long range coverage for its Infinia Long Range radio system. Guided by rules of physics, the lower the frequency is, the greater distance it can travel, yet low frequencies are sensitive to other issues. VHF (Very High Frequency) and UHF (Ultra High Frequency) radio waves travel in LOS (“Line-of-Sight”), which defines their maximum communication range. High frequency (HF) radio communications can reach beyond line of sight by using the ionosphere to refract radio signals back to earth. GBT is now conducting a hybrid-evaluation and testing to combine the two frequency’s ranges...

Oyster Point Pharma Announces Preclinical Data Highlighting Potent Activity of OC-01 (varenicline) and OC-02 (simpinicline) Against SARS-CoV-2 Virus and Variants

Written by Customer Service on July 1, 2021. Posted in Public Companies.

Administration of OC-01 (varenicline) nasal spray to non-human primates was observed to inhibit viral replication in the nose within 24 hours of infectious SARS-CoV-2 challenge with absence of subgenomic RNA at Day 3 and Day 5 post-challengeVarenicline inhibits cellular entry and replication of SARS-CoV-2 and its alpha and beta variants in multiple human cell typesSimpinicline inhibits cellular entry and replication of SARS-CoV-2 alpha variant in Calu-3 human cells with additional variants under investigationOyster Point Pharma collaborates with the Trudeau Institute for in vitro testing of varenicline, the active ingredient in OC-01 nasal spray and simpinicline, the active ingredient in OC-02 nasal sprayOyster Point Pharma plans to present data at the upcoming Analyst Day, scheduled for July 15, 2021PRINCETON, N.J., July...

U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Written by Customer Service on July 1, 2021. Posted in Public Companies.

– U.S. FDA has assigned a target action date of April 30, 2022 – – If approved, surufatinib would be HUTCHMED’s first novel oncology drug marketed outside of China – HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 01, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the U.S. Food and Drug Administration (“FDA”) has accepted its filing of the New Drug Application (“NDA”) for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors (“NETs”). The Prescription Drug User Fee Act (PDUFA) goal date assigned by the FDA for this NDA is April 30, 2022. Surufatinib received fast track designation in April 2020 for the treatment of pancreatic and extra-pancreatic NET. Orphan Drug Designation for pancreatic NET was also granted...

Day: July 1, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals